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Summary We have defined a novel ovarian cancer-associated membrane antigen, 14C1, using human
monoclonal antibodies derived by EBV-transformation of in situ sensitised patients' B-cells. The pattern of
recognition of this antigen by these antibodies suggests that at least three epitopes are discernable. These
antibodies can be used to promote the in vitro killing of ovarian cancer cells by activated macrophages and
cytokines, implying a role for this antigen in the immunotherapy of ovarian malignancies. Evidence is
presented that the 14C1 antigen may have some transmembrane signalling function.
Ovarian cancer continues to kill significant numbers of
women every year. The recent development of aggressive,
platinum-based chemotherapeutic protocols has delayed the
onset of post-surgical recurrence, but the overall survival is
still poor (Slevin, 1986).
Recent years have seen the description and development of
several mouse monoclonal antibodies as potential diagnostic
agents and/or therapeutic tools in the monitoring and treat-
ment of ovarian cancer. One in particular, CA-125, is used
extensively in the routine post-surgical monitoring of these
patients (Sekine et al., 1985) and another, HMFG-2, has
been used for the treatment and imaging of intra-peritoneal
residual disease following surgery (Ward et al., 1988). In
addition, a number of other antibodies have been described
which usually (Sakakibara et al., 1988), but not always (Mat-
tes et al., 1987), define high molecular weight mucinous or
carbohydrate antigens.
In several cases, murine antibodies such as HMFG2 have
shown good clinical potential in ovarian cancer, particularly
for the treatment of recurrent ascites rather than solid metas-
tatic nodules (Ward & Wallace, 1987). However, murine
antibodies are known to solicit an 'anti-mouse' response
from the human immune system (Pimm et al., 1985; Rey-
nolds et al., 1986) and this could seriously diminish their
clinical usefulness. Although such materials can be 'human-
ised', the most satisfactory procedure would be to use a
wholly human antibody, provided one of the correct
specificity could be found.
Additionally, although antibodies raised in mice are un-
doubtedly of great clinical use, they describe moieties which
are antigenic in mice and so may not reflect the antigenicity
of a particular tumour type in the human host. Working
from the premise that antibody bound to tumour in situ will
be specifically directed against that tumour, the production
of human, anti-cancer antibodies from Epstein-Barr virus-
transformed human lymphocytes has been investigated. A
small number of such antibodies has been reported, partic-
ularly for melanoma and breast or colonic tumours (Haspel
et al., 1985; Kan-Mitchell et al., 1986; Kjeldsen et al., 1988).
In a previous study (Gallagher et al., 1991a), we described
the partial characterisation of an antigen, '14C1', defined
with a human antibody produced by EBV-transformation of
the lymph-node cells of ovarian cancer patients (Al-Azzawi et
al., 1987), and demonstrated its membrane expression. The
expression of 14C1 was highly restricted to ovarian epithelial
tumours, particularly of the clear-cell carcinoma and serous
or mucinous cystadenocarcinoma types, of which 88% were
positive. A wide range of other normal and malignant tissue
did not express the 14C1 antigen. We consider this antigen to
be particularly important because it has been defined by a
human antibody derived from the B-cells in an involved
lymph-node; strongly suggesting that this antigen was the
object of an anti-tumour immunological response at the time
of resection. Such an antigen may represent a potent target
for both active and passive immunotherapy in the post-
surgical treatment of ovarian cancer. For this reason, we
examined a range of anti-14C1 antibodies and investigated
their utility as tools for marking the antigen, with particular
reference to directing cellular effectors against the tumour.
We describe here the definition of three epitopes on the
14C1 antigen and the use of one particular antibody to kill
ovarian cancer cells in vitro by monocyte-mediated ADCC.
We further report the observation that the 14CI antigen may
have some transmembrane signalling function.
Materials and methods
Preparation ofthe anti-14C1 secreting cell-lines
The anti-14CI secreting cell-lines were prepared and selected
as previously described (Al-Azzawi et al., 1987; Gallagher et
al., 1991a). All antibodies are IgG. For antibodies a14CL.1,
axl4C1.2 and a14C1.3, lymph-nodes were obtained from a
patient undergoing cytoreductive surgery for ovarian epi-
thelial cancer at Stobhill General Hospital, Glasgow. Follow-
ing dissociation of the nodes in vitro, T-cells were removed
by two rounds of rosetting with AET-treated sheep eryth-
rocytes and the resulting cells exposed to live Epstein-Barr
virus (as the supematant of the marmoset cell line, B95/8) for
2 h at 37°C. Following thorough washing, the cells were
seeded at a density of 5 x IO' ml-' (200 pl cultures) in 96-
well, flat-bottom plates (Costar). Wells were selected for the
presence of antibody able to bind to the human ovarian
cancer cell-line 'OWmMl' (a generous gift from Professor
C.N. Hudson, St. Bartholomew's Hospital, London, and
made available to us by Professor W.H. Stimson, Immun-
ology Research Group, University of Strathclyde). Stable
secretors were selected by multiple, repeated selection. For
the production of antibodies al4Cl .4 and al4CI.5, cells were
obtained from the peripheral blood of a patient undergoing
active, specific immunotherapy for their ovarian tumour, as
previously described (Al-Azzawi, 1988). Peripheral blood B-
cells were isolated, transformed and secreting lines selected as
described for the lymph-node cells. The characterisation of
these antibodies is described elsewhere (Al-Azzawi et al., in
submission).
The antibody producing and target cell lines were main-
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tained in Ham's FlO culture medium, containing 10% (v/v)
foetal calf serum and 2 mM glutamine (complete medium; all
media components were obtained from Biological Industries
Ltd).
Preparation oftumour samplesfor analysis
After histological confirmation of malignancy, a sample of
non-necrotic tissue was chopped finely and pressed through a
nylon mesh to release tumour cells. These cells were lysed in
a lysis buffer, comprising 0.5% (w/v) Nonidet P40 and
0.1 mM phenylmethylsulphonylfluoride (PMSF) in phos-
phate-buffered saline, pH 7.4 (PBS; all reagents from Sigma),
at 4°C for 30 min. Cell membranes were prepared by cen-
trifugation of the lysis mixture (400g, 10 min) and subjecting
the supernatant to further centrifugation (15,000 g, 45 min,
4°C). The supernatants from this procedure were designated
"membranes' and adjusted to 2 mg ml-' protein (Bradford's
method) before use in Western Blotting experiments.
Western blotting
Membrane preparations were subjected to polyacrylamide gel
electrophoresis in the presence of sodium dodecyl sulphate,
under reducing conditions (SDS-PAGE), using an LKB
'Midget gel' apparatus and 15% resolving gels of 0.75 mm
thickness. Membrane samples were diluted to 0.5 mg ml-'
protein in sample buffer (62.5 mM tris, 2% (w/v) SDS, 10%
(v/v) glycerol, 4% (v/v) 2-mercaptoethanol, 0.1 mg ml-' bro-
mophenol blue) and boiled for 5 min before loading 5-10 yg
protein to each track. Following separation, proteins were
electrophoretically transferred to nitrocellulose membrane
('Hybond-C', Amersham International) using a Biorad
'Transblot' apparatus, under 'wet' conditions in a transfer
buffer comprising 20 mM tris, 192 mM glycine, 1% (w/v) SDS
and 25% (v/v) methanol. Transfer was conducted for at least
2 h at 100 volts. Prestained molecular weight markers
(Sigma) were used to calibrate the finished blots: 26.6 kD
(triosephosphate isomerase) and 48.5 kD (fumarase).
Blots were 'blocked' by incubating in complete medium for
1 h at room temperature, then stained with 400 ng ml-' of
the appropriate anti-14C1 antibody in complete medium for
a further 90 min. Following thorough washing in PBS
containing 0.05% (v/v) Tween-20 (PBS-Tween; Sigma), alka-
line-phosphatase conjugated, goat anti-human IgG ('y-chain
specific; Sigma) was diluted 1:1000 in PBS-Tween and added
for 1 h at room temperature, after which time the blot was
again extensively washed. The washed blots were equilibrated
in substrate buffer (100 mM tris, 25 mM diethanolamine,
100 mM NaCl, 2 mM MgC12; pH 9.55) and the bands vis-
ualised by exposure to a substrate solution comprising
0.33 mg ml-' nitrobluetetrazolium in substrate buffer, to each
ml of which was added 6.7ILl of 2 mg ml-' phenazine metho-
sulphate in water and 3.4 LI of 40 mg m'l 5-bromo-4-chlo-3-
indolyl phosphate (p-toluidine salt) in dimethylformamide
(all reagents from Sigma), according to the method of Ey
and Ashman (1976). Under these conditions, the conjugate
detects not only the test antibody (if bound) but also IgG
heavy chain already present in the sample, which therefore
appears in all the tracks at around 48 kD; in some cases,
heavier bands at 80-120 kD are also detected by this con-
jugate in membrane preparations. The conjugate does not
detect either kappa or lambda light chain nor any other
material lighter than heavy chain.
Cell-ELISA
In order to investigate the binding of the various antibodies
to the OWmM1 cell-line, a 'Cell-ELISA' was carried out, as
previously described (Al-Azzawi et al., 1987).
In vitro cytotoxicity assay
The ovarian cancer cell-line OWmM1 was used as the target
cell in all cases; we have previously shown this line to have
characteristics associated with primary human ovarian tu-
mours (Al-Azzawi et al., 1987; Gallagher et al., 1989).
The cytotoxicity assay used was developed from that of
Johnson and Adams (1986), where target cell DNA was
labelled with 3H-thymidine. Monocytes were isolated from
the peripheral blood of healthy adult volunteers in a single
step by centrifugation over the density separation medium
'Monodenz' (Nycomed). Monocytes were activated by a 24 h
exposure to supernatant (diluted 1:1 with complete medium)
from 4-day mixed lymphocyte cultures (MLC; human), from
which the immunoglobulin had been removed by passage
over Protein-A Sepharose (Pharmacia-LKB); MLC were car-
ried out in complement-depleted foetal calf serum. Activated
monocytes were washed (x 3) prior to use. MLC super-
natants prepared in this way contain a number of cytokines
known to activate monocytes to cytotoxicity, including y-
interferon, interleukin-4, interleukin-2 and granulocyte/mac-
rophage colony stimulating factor (Nathan et al., 1984;
Crawford et al., 1987; Malkovsky et al., 1987; Grabstein et
al., 1986; Cannistra et al., 1987).
Target cells were seeded to semi-confluence in 96-well
plates (Costar) in 100IlI complete medium, containing 10lsCi
ml-' 3H-thymidine (TRK 328; Amersham) and allowed to
grow for 24 h. After this time, the cells were virtually
confluent, totally adherent and would generally have
incorporated 30,000-60,000 c.p.m. per well. The
radiolabelled culture fluid was removed and the cells sub-
jected to four rounds of medium exchange (200 lI), with a
10 min period between to allow diffusion of unbound label
from the cell. Subsequent spontaneous release of label from
the cells was found to be less than 5%.
Anti-14CI antibody (14ClI.) was added at various concen-
trations (see Results) and incubated for 1 h after which it was
removed, the cells washed twice by medium exchange and the
activated monocytes added (E:T = 10:1): killing was allowed
to proceed for 24 h. After this period, both monocytes and
dead target cells were removed by repeated gentle washing
and the remaining (live) cells lysed with 150fsl of a 1% (w/v)
solution of sodium dodecyl sulphate (Sigma) in distilled
water. The radioactivity contained in 100ly1 of this lysate
(and hence percentage live cells remaining; PLCR) was
determined and taken as a simple fraction of the total
radioactivity incorporated (target cells labelled and thereafter
untreated, then lysed). The 'Percentage Killing' was calcu-
lated as 'PK = 100 - PLCR'. Controls (see Table I) included:
14ClI. alone; 14ClI. + resting monocytes; resting or acti-
vated monocytes alone, or in combination with 1ltg ml-'
human myeloma IgG (as irrelevant antibody). In no case was
significant killing observed unless activated monocytes were
present. Higher degrees of killing were dependent upon the
presence of activated monocytes and related to the amount
of 14Cl. antibody present (see Figure 3).
Results
Western blotting with different anti-14CJ antibodies suggests
the presence ofdiscrete epitopes on the 14C1 antigen
We have previously described how the 14C1 antigen appears
as a single band on primary ovarian malignant tissue (Gal-
lagher et al., 1991a). Using the five antibodies now available,
we extended the study to include samples of serous cys-
tadenocarcinoma, mucinous cystadenocarcinoma and clear-
cell carcinoma of the ovary and we investigated whether all
the antibodies described the same distribution pattern or
whether this would vary with the antibody. The results are
shown in Figure la-e.
Figure 1 shows Western Blot analysis of representative
primary tissue specimens, visualised with the antibodies
axl4Cl.1 to al4Cl.5. The tissues analysed are; vaginal (Figure
la), colorectal carcinoma (Figure lb, mucinous cystadeno-
carcinoma of the ovary (Figure lc), serous cystadenocar-
cinoma of the ovary (Figure ld) and clear cell carcinoma of
the ovary (Figure le). In each case, the same antibodies wereANTI-14C1 ANTIBODIES AND OVARIAN CANCER 37
used for blotting; track A: al4Cl.l; track B: al4Cl.2; track
C: al4CI.3; track D: al4Cl.4; track E: al4Cl.5.
In the case of all five tissue specimens, a heavy band
appears around the 48 kD mark, which is known to be due
to the direct detection of IgG heavy chain from IgG con-
taminating the sample. The faint bands present at higher
molecular weights in all five samples are not defined, but
have been disregarded from our analysis since they are com-
mon to all tissues tested here and are visualised by the
conjugate alone (not shown) and are therefore not related to
the tumour type.
The bands below the 48 kD region are held to be spec-
ifically detected on ovarian cancer specimens (Gallagher et
al., 1991a). In some cases a single band is detected (for
example, track A, Figure lc) and in others a double band is
observed (track A, Figure ld), at or around the 25 kD mark.
A 32 kDa antigen is also detected by all antibodies on all
tumours, except for the case of antibody al4Cl1.3 and the
mucinous tumour. A clear difference in the bands recognised
by the different antibodies is shown, suggesting that the
antibodies are recognising different epitopes on the peptide
chains which make up the 14C1 antigen. After consideration
of the pattern of antibody binding, we believe that three
epitopes are being detected over the three tumour types.
Relative binding ofthe anti-14C1 antibodies to the 14C1
antigen
In order to gain some insight into the use of these antibodies
as targeting agents in models of ovarian cancer based round
the OWmM1 cell line, we investigated their relative ability to
bind to this cell line, in a cell-ELISA. All five antibodies were
tested and found to give similar, but distinct levels of bin-
ding.
The binding curves for the antibodies which exhibited the
highest (al4Cl.l) and the lowest (al4Cl.2) binding are
shown in Figure 2; it can be seen that there is a 10-fold
difference in binding between these two antibodies and
xl4Cl.1 was therefore used in further studies (below). This
difference will reflect a combination of epitope density and
binding affinity and is probably applicable only to this cell-
line under our assay conditions; we fully expect that the
relationship between these antibodies will be different on
primary samples and this is an area of current investigation.
Given the utility of the OWmMl line is an in vitro and in
vivo model of human ovarian cancer however (Gallagher et
al., in submission 1991b), we feel that it is relevant to draw
attention to differences in antibody binding to these cells.
Activated monocytes can utilise the alJ4CL.I antibodiesfor
ADCC-mediated killing of0WmMJ
As part of a programme to investigate the use of the 14C1
antigen as a possible target structure for immunotherapy of
ovarian cancer, we attempted to kill these cells with the
al4Cl.l antibody and activated peripheral blood monocytes
as ADCC effectors. OWmM1 cells were labelled as described
and exposed to activated effector cells in the presence of
increasing amounts of antibody. As shown in Table I, killing
was wholly dependent upon the presence of specific antibody
together with activated effector cells. That the antibody was
acting to form a 'bridge' between the effector and target cells
is indicated in Figure 3, where antibody-dependent killing
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Figure 1 Different antibodies appear to detect different epitopes
of the 14C1 antigen. Membrane preparations were derived from
tissue samples, and subjected to Western Blotting as described in
the text. a, vaginal tissue; b, colon carcinoma; c, mucinous cysta-
denocarcinoma of the ovary; d, serous cystadenocarcinoma of the
ovary; e, clear cell carcinoma of the ovary. Banding was vis-
ualised following staining with the following anti-14C1 anti-
bodies; al4CL.I (track A); al4Cl.2 (track B); al4CI.3 (track C);
al4CI.4 (track D) and al4CI.5 (track E).
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observed to occur, beginning at levels of antibody previously
shown to give significant binding to the target cells (Figure
2). ADCC reached 68%, while activated effectors alone
usually caused 15-20% lysis.
Table I Evidence ofantibody dependent killing ofovarian cancercells




Myeloma IgG alone 0
Resting monocytes aloneb 5.43 ± 1.20c
Resting monocytes plus myeloma IgG 6.90 ± 0.28
14C1.1 plus resting monocytes 8.04 ± 0.41
Activated monocytes alone 15.22 ± 4.86
Activated monocytes plus myeloma IgG 18.03 ± 3.37
14C1.l plus activated monocytes 68.77 ± 9.72
aAntibodies were added at 250 ng IgG perml. "The effector to target
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Figure 2 Differential binding of anti-14CI antibodies the cell-
borne 14C1 antigen. Using a 'cell-ELISA' assay, the binding of
anti-14C1 antibodies to the antigen was compared as described in
the text. The results showed that antibody al4Cl.1 ( U)
showed measurable binding at an antibody concentration 10-fold
lower than that required for the least avid antibody, al4CI.2
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Figure 3 Anti-14Cl antibody allows ADCC style killing of ovar-
ian cancer cells in vitro. The ovarian cancer cell-line OWmM
was radiolabelled, pre-coated with a range of concentrations of
the anti-14Cl antibody 14Cl1.1 and exposed to activated mono-
cytes at an effector-to-target cell ratio of 10:1, as described in the
text. Significant killing was observed, which was seen to be
dependent upon the concentration of antibody used. For con-
trols, see Table I. Results are expressed as the mean ± std.dev.
of at least five observations.
Synergy between the al4CL.J antibody and TNF-L in the
killing ofOWmMI
It has been suggested that monocyte-mediated killing is car-
ried out largely by tumour-necrosis factor (TNF-a; (Fein-
mann et al., 1987)) associated with the cell membrane
(Decker, Lohmann-Mattes & Gifford, 1987). Accordingly, we
tested the hypothesis that target cell killing was due to the
action of TNF-x, brought into contact with the target cells
on the activated monocytes, which had themselves been
localised via the antibody. The experimental results are
shown in Table I and Figure 4. These data shown that
TNF-a alone is not sufficient to kill OWmMl cells. However,
a titration of TNF-z in the presence of 50ngml1' al4ClI.
antibody showed TNF-dose dependent killing, suggesting
synergy between these two molecules in the killing of
OWmMl.
Discussion
We have used EBV-transformation to prepare human IgG-
secreting cell-lines from the involved lymph-nodes and per-
ipheral blood ofovarian epithelial cancer patients (Al-Azzawi
et al., 1987; Al-Azzawi et al., in submission) and demon-
strated that they secrete antibodies able to recognise an
antigen on this tumour with a high degree of selectivity.
We have termed this antigen '14C1' and the corresponding
antibodies 'al4Cl.l', '14C1.2', 'al4Cl.3', 'al4Cl.4' and
'al4Cl.5'. The restriction of distribution of the 14C1 antigen
to the membranes of certain ovarian tumour types has
already been demonstrated (Gallagher et al., 1991a). The fact
that the antibodies produced different binding patterns on
the three tumour types tested (while none recognised the two
control samples), strongly suggests that each antibody recog-
nised the 14C1 antigen. The antigen appears at both 32 and
26 kDa.
The reasons as to why the 14C1 antigen appears at both 26
and 32 kDa (with either single or double banding at each
weight) are unclear at present, but they may indicate that the
14C1 molecule is subject to proteolytic cleavage at or close to
the outer surface of the membrane, as has been documented
for a variety of growth factor receptors, such as CD23 and
CD25, or it may result from the processing procedure 'fixing'
partly processed forms ofthe molecule (as has been described
for the EGF receptor; Gill et al., 1987). Alternatively, these
bands may represent different glycoforms of the antigen.
Studies to formally address these questions are underway.
In addition, it appears that several epitopes are being
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Figure 4 Synergistic killing of OWmMl by TNF and antibody
14Cl.1. OWmMI cells were labelled as in Figure 3 and exposed
to increasing concentrations of human TNF-x in the presence
( *-) or absence (0-0) of 50ngml-' antibody al4Cl.l.
The results suggest that TNF-mediated killing is only able to
proceed in the presence of the antibody. Results are expressed as
the mean ± std.dev. of at least five observations.
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recognised; for example, al4CI.1 (track A) and al4CI.2
(track B) recognised the light and heavy bands on all three
tumours, while al4CI.4 (track D) and al4CI.5 (track E)
recognised only the 32 kDa band in the mucinous tumour,
but both the light and heavy bands in the other two tumours.
The different binding pattern of these two groups of anti-
bodies on the mucinous tumour suggests strongly that they
are not recognising the same epitope (otherwise the light
bands would have appeared in tracks D and E). The light
bands in tracks D and E in the serous and clear-cell tumours
may again represent different glycoforms or cleavage prod-
ucts of the antigen. The recognition of the tumours in track
C is again different; no binding to mucinous and only a
single band of intermediate weight on the serous tumour,
with two bands at 26 and 32 kDa on the clear-cell tumour.
We consider the results to provide compelling (though we
agree, not definitive) evidence for the recognition of a third
discrete epitope. Although we cannot rule out the possibility
that different glycoforms of the antigen do exist (and this
may have great implications for the pathology of the tumour
(Neale et al., 1990)), the apparent cooperation in killing
between al4C1 and TNFa leads us to favour the growth-
factor receptor model which would predict that the 14C1
molecule is subject to cleavage at or close to the membrane,
resulting in the two molecular weight forms being identified
from tissue.
We are attempting to develop possible therapeutic applica-
tions directed against the 14C1 antigen. One of the most
appealing is to use the antibodies in the context of intra-
peritoneal ADCC. The contained environment within which
ovarian cancers are found enhances the potential utility of
this approach; macrophages are obvious effectors since it has
been shown that they are capable of killing tumour cells by
this method and are prevalent within the peritoneal cavity
(Adams et al., 1984; Johnson & Adams, 1986; Lubeck et al.,
1988). In addition, activated macrophages adoptively trans-
ferred into the human peritoneal cavity remain there for
several days (Stevenson et al., 1987). The results described in
this report clearly illustrate that the 14C1.1 antibody is
capable of allowing cytokine-activated peripheral blood mon-
ocytes to kill ovarian cancer cells in vitro, by an ADCC
mechanism (Figure 2) and so suggest a therapeutic potential
for this reagent. It has been suggested that this form of
killing is largely mediated by TNF-a (Zeigler-Heitbrock et
al., 1986), particularly membrane-associated TNF (Decker et
al., 1987). The results shown in Figure 4 show that the
OWmM1 cell-line is sensitive to TNF and so the observed
ADCC may be due to release of this factor. It was unex-
pected to note that this sensitivity to TNF was dependent
upon the presence of the antibody and we can only conclude
that antibody binding to the 14C1 molecule renders the cell
TNF-sensitive, perhaps by some mechanism which initiates
synthesis of the TNF receptor; thus it is possible that 14C1
has some transmembrane signalling function.
Cytokines have been used successfully in the treatment of
experimental models of human ovarian cancer (Balkwill et
al., 1987), particularly those protocols which centre round
TNF. Similarly, murine antibodies have been found to be of
benefit, particularly for the treatment of recurrent ascites
rather than solid metastatic nodules (Ward & Wallace, 1987).
The results presented in this report strongly suggest that the
therapeutic efficacy of such agents would be greatly enhanced
if used together.
In conclusion, we believe that the antibodies described here
may be of clinical use in ovarian cancer. The further analysis
of such anti-tumour responses involving 14C1 may provide
tools with which the immune system can be manipulated as
part of the post-surgical management of ovarian cancer.
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